Newron Pharmaceuticals S.p.A. (0QOI.L)
CHF 7.54
(6.95%)
CHF 7.54
(6.95%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 20.68 Million EUR | 5.14% |
| 2022 | 19.67 Million EUR | 10.65% |
| 2021 | 17.78 Million EUR | -21.66% |
| 2020 | 22.69 Million EUR | -15.37% |
| 2019 | 26.81 Million EUR | 40.27% |
| 2018 | 19.12 Million EUR | 1.44% |
| 2017 | 18.84 Million EUR | -14.47% |
| 2016 | 22.03 Million EUR | -19.83% |
| 2015 | 27.48 Million EUR | 121.89% |
| 2014 | 12.38 Million EUR | 9.47% |
| 2013 | 11.31 Million EUR | -2.63% |
| 2012 | 11.62 Million EUR | 71.86% |
| 2011 | 6.76 Million EUR | -69.87% |
| 2010 | 22.44 Million EUR | -17.17% |
| 2009 | 27.09 Million EUR | 21.78% |
| 2008 | 22.25 Million EUR | 25.19% |
| 2007 | 17.77 Million EUR | -0.94% |
| 2006 | 17.94 Million EUR | 19.02% |
| 2005 | 15.07 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 11.09 Million EUR | 0.0% |
| 2023 Q2 | 10.44 Million EUR | 0.0% |
| 2023 FY | 20.68 Million EUR | 5.14% |
| 2023 Q4 | 10.88 Million EUR | 0.0% |
| 2022 FY | 19.67 Million EUR | 10.65% |
| 2022 Q2 | 9.57 Million EUR | 0.0% |
| 2022 Q4 | 10.09 Million EUR | 0.0% |
| 2021 Q2 | 10.46 Million EUR | 0.0% |
| 2021 Q4 | 7.31 Million EUR | 0.0% |
| 2021 FY | 17.78 Million EUR | -21.66% |
| 2020 FY | 22.69 Million EUR | -15.37% |
| 2020 Q4 | 10.66 Million EUR | 0.0% |
| 2020 Q2 | 12.03 Million EUR | 0.0% |
| 2019 Q4 | 10.52 Million EUR | 0.0% |
| 2019 FY | 26.81 Million EUR | 40.27% |
| 2019 Q2 | 16.29 Million EUR | 0.0% |
| 2018 Q2 | 9.59 Million EUR | 0.0% |
| 2018 Q4 | 9.52 Million EUR | 0.0% |
| 2018 FY | 19.12 Million EUR | 1.44% |
| 2017 Q2 | 10.13 Million EUR | 0.0% |
| 2017 FY | 18.84 Million EUR | -14.47% |
| 2017 Q4 | 8.71 Million EUR | 0.0% |
| 2016 Q2 | 12.77 Million EUR | 0.0% |
| 2016 FY | 22.03 Million EUR | -19.83% |
| 2016 Q4 | 9.25 Million EUR | 0.0% |
| 2015 FY | 27.48 Million EUR | 121.89% |
| 2015 Q2 | 8.94 Million EUR | 0.0% |
| 2015 Q4 | 18.54 Million EUR | 0.0% |
| 2014 Q4 | 6.35 Million EUR | 0.0% |
| 2014 FY | 12.38 Million EUR | 9.47% |
| 2014 Q2 | 6.03 Million EUR | 0.0% |
| 2013 Q4 | 6.69 Million EUR | 6000.23% |
| 2013 FY | 11.31 Million EUR | -2.63% |
| 2013 Q3 | 109.75 Thousand EUR | -97.59% |
| 2013 Q2 | 4.55 Million EUR | 0.0% |
| 2012 Q1 | 230 Thousand EUR | 0.0% |
| 2012 Q2 | 230 Thousand EUR | 0.0% |
| 2012 FY | 11.62 Million EUR | 71.86% |
| 2012 Q3 | 230 Thousand EUR | 0.0% |
| 2012 Q4 | 109.75 Thousand EUR | -52.28% |
| 2011 Q3 | -1 Million EUR | 0.0% |
| 2011 Q1 | -1 Million EUR | 0.0% |
| 2011 Q2 | -1 Million EUR | 0.0% |
| 2011 FY | 6.76 Million EUR | -69.87% |
| 2011 Q4 | 230 Thousand EUR | 122.95% |
| 2010 Q3 | 5.61 Million EUR | 0.0% |
| 2010 FY | 22.44 Million EUR | -17.17% |
| 2010 Q1 | 5.61 Million EUR | 0.0% |
| 2010 Q4 | -1 Million EUR | -117.86% |
| 2010 Q2 | 5.61 Million EUR | 0.0% |
| 2009 Q4 | 5.61 Million EUR | -17.17% |
| 2009 FY | 27.09 Million EUR | 21.78% |
| 2009 Q3 | 6.77 Million EUR | 0.0% |
| 2009 Q2 | 6.77 Million EUR | 0.0% |
| 2009 Q1 | 6.77 Million EUR | 0.0% |
| 2008 Q2 | 5.56 Million EUR | 0.0% |
| 2008 Q1 | 5.56 Million EUR | 0.0% |
| 2008 FY | 22.25 Million EUR | 25.19% |
| 2008 Q4 | 6.77 Million EUR | 21.78% |
| 2008 Q3 | 5.56 Million EUR | 0.0% |
| 2007 Q3 | 4.44 Million EUR | 0.0% |
| 2007 Q2 | 4.44 Million EUR | 0.0% |
| 2007 Q1 | 4.44 Million EUR | 0.0% |
| 2007 FY | 17.77 Million EUR | -0.94% |
| 2007 Q4 | 5.56 Million EUR | 25.19% |
| 2006 FY | 17.94 Million EUR | 19.02% |
| 2006 Q1 | -41 Thousand EUR | 0.0% |
| 2006 Q3 | -41 Thousand EUR | 0.0% |
| 2006 Q2 | -41 Thousand EUR | 0.0% |
| 2006 Q4 | 4.44 Million EUR | 10938.41% |
| 2005 Q3 | -16.75 Thousand EUR | 0.0% |
| 2005 Q1 | -16.75 Thousand EUR | 0.0% |
| 2005 Q2 | -16.75 Thousand EUR | 0.0% |
| 2005 FY | 15.07 Million EUR | 0.0% |
| 2005 Q4 | -41 Thousand EUR | -144.78% |
| 2004 Q4 | -16.75 Thousand EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Relief Therapeutics Holding AG | 114.94 Million CHF | 82.003% |
| Tecan Group AG | 254.49 Million CHF | 91.872% |
| Santhera Pharmaceuticals Holding AG | 31.33 Million CHF | 33.984% |
| Basilea Pharmaceutica AG | 111.63 Million CHF | 81.47% |
| Bachem Holding AG | 47.58 Million CHF | 56.526% |
| Siegfried Holding AG | 148.34 Million CHF | 86.055% |
| Molecular Partners AG | 20.3 Million CHF | -1.891% |